Search Orphan Drug Designations and Approvals
-
| Generic Name: | ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15 |
|---|---|
| Date Designated: | 03/07/2023 |
| Orphan Designation: | Treatment of gastric and gastroesophageal junction cancer |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Artiva Biotherapeutics, Inc. 5505 Morehouse Drive Suite 100 San Diego, California 92121 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







